Vertex to Acquire Crinetics for $10 Billion with a 102% Premium
Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in a cash deal valued at approximately $10 billion, representing a significant premium over the latter's stock price. The acquisition targets Crinetics' FDA-approved drug Palsonify and its promising pipeline candidate Atumelnant.
Topics: FDA approval M&A pharmaceuticals